FDA Clears Registrational C-CAR168 Study in Lupus Nephritis

Company AbelZeta Event Type Regulatory Clearance (FDA, Registrational Phase II) Modality Autologous CAR-T cell therapy (dual CD20/BCMA targeting) Asset C-CAR168 Target CD20 and BCMA (dual B-lineage and plasma-cell depletion) Disease Area Refractory lupus nephritis Summary FDA cleared AbelZeta to initiate a registrational Phase II study…